Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

John Carroll

Editor & Founder

Every biotech startup sets out at its own idea of a deliberate pace. And they often fall into 2 separate styles.

There are the sprinters who leap straight into a slate of deals, looking to align themselves with the kind of blue chip partners that help validate their place in the development pipeline.

And then there are the marathon, long-haul biotechs like Arrakis, which take a more measured approach.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

John Carroll

Editor & Founder

To read Endpoints News become a free subscriber

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Roche makes a plat­form play, bet­ting $190M in cash on Ar­rakis’ long-haul plans to drug RNA

John Carroll

Editor & Founder

To read Endpoints News become a free subscriber

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape